Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO) | LUNG CANCER |